Business Context and Reporting Period
Company: The Chemours Company (CC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Chemours is a global provider of performance chemicals, reporting through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The company operates under a "Pathway to Thrive" strategy, focusing on cost optimization and portfolio enhancement.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $1,381 | $1,368 |
| Gross Profit | $212 | $236 |
| Gross Margin | 15.4% | 17.3% |
| Net Loss | $(29) | $(5) |
| Diluted EPS | $(0.19) | $(0.03) |
| Operating Cash Flow | $(44) | $(112) |
| Free Cash Flow (approx.) | $(93) | $(196) |
| Total Debt (Principal) | $4,183 | $4,182 |
| Cash & Equivalents | $563 | $670 |
| Revolving Credit Availability | $953 | N/A |
Material Changes vs. Prior Period
- Revenue: Net sales increased 1% year-over-year, driven by a 2% price increase and 3% favorable currency impact, offset by a 4% volume decrease.
- Profitability: Net loss widened significantly from $5 million to $29 million. This was primarily due to a $9 million loss on debt extinguishment, $20 million in litigation-related charges, and $7 million in environmental charges.
- Segment Performance:
- Thermal & Specialized Solutions: Sales up 22% and Adjusted EBITDA up 35% to $190 million, driven by strong refrigerant demand and pricing.
- Titanium Technologies: Sales down 6% and Adjusted EBITDA down 64% to $18 million due to lower volumes and input costs.
- Advanced Performance Materials: Sales down 17% and Adjusted EBITDA down 84% to $5 million, impacted by a $25 million operational disruption at the Washington Works site and the exit of the SPS Capstone business.
- Restructuring: Charges decreased 61% to $13 million, primarily related to the 2026 Restructuring Program ($9 million) and SPS Capstone exit ($4 million).
Guidance, Outlook, and Risks
- Capital Allocation: In March 2026, the company issued $700 million of 7.875% Senior Notes due 2034 to redeem $683 million of older debt (2027 and 2028 notes), resulting in a $9 million loss on extinguishment. This activity is expected to increase annual interest expense by approximately $9 million.
- Asset Sale: In April 2026 (post-period), the company sold nine parcels of land in Taiwan for net proceeds of $287 million, expecting to recognize a $265 million gain in Q2 2026.
- Liquidity: Management believes liquidity is sufficient through May 2027. Unrestricted cash is $563 million with $953 million available under the revolving credit facility.
- Legal & Environmental Risks:
- PFAS Litigation: Significant exposure remains regarding PFAS (including PFOA and GenX). The company has accrued $491 million for litigation, including a $266 million net present value accrual for a New Jersey settlement (totaling $875 million over 25 years).
- Regulatory: Ongoing EPA and EU regulatory actions regarding PFAS restrictions and drinking water standards could increase remediation liabilities.
- Operational: The Washington Works site disruption in Q1 2026 caused a $25 million earnings impact; future permit renewals remain a risk.
Investor Verification Checklist
- Debt Refinancing Impact: Verify the net increase in annual interest expense following the March 2026 bond issuance and redemption.
- Taiwan Land Sale: Confirm the timing and tax implications of the $265 million gain expected in Q2 2026 from the Taiwan land sale.
- PFAS Liability Exposure: Review the $491 million accrued litigation balance and the potential for additional costs from the New Jersey settlement and ongoing EPA actions.
- Washington Works Recovery: Monitor the operational status of the Washington Works site and the impact of the $25 million Q1 disruption on full-year guidance.
- Working Capital Seasonality: Note the historical pattern of working capital cash usage in the first half of the year, which contributed to the $44 million operating cash outflow.